LA JOLLA, Calif., April 20, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and?Trademark Office?for a pending patent application which covers MN-166 (ibudilast) for the treatment of glioblastoma. ?This new patent has improved therapeutic claims compared to the first patent which covers MN-166 (ibudilast) for the treatment of glioblastoma, which was granted last year, and has a later expiration date than the first patent.
News
MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology
LA JOLLA, Calif., June 25, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive preclin… […]
News
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China
LA JOLLA, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the?NASDAQ Global Market?(NASDAQ:MNOV) and the JASDAQ Market of the?Tokyo Stock Exchange?(Code Number: 4875), today announced that it has rec… […]
News
MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS
LA JOLLA, Calif., July 11, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its plans for a … […]
